Clinical Trials in Lake Forest, California

23 recruiting

Showing 120 of 23 trials

Recruiting
Phase 3

Long-Term Safety and Efficacy of Plozasiran in Adults With Hypertriglyceridemia

Hypertriglyceridemia
Arrowhead Pharmaceuticals869 enrolled248 locationsNCT06822790
Recruiting
Phase 2

A Study to Learn About the Study Medicine Called PF-07328948 in Adults With Heart Failure (BRANCH-HF)

Heart Failure
Pfizer620 enrolled135 locationsNCT06991257
Recruiting
Phase 1

A Study to Learn About a Vaccine Against E Coli in Healthy Adults

Healthy Participants
Pfizer310 enrolled11 locationsNCT07122986
Recruiting
Phase 3

A Study to Test Whether Vicadrostat (BI 690517) in Combination With Empagliflozin Helps People With Heart Failure and a Weak Pumping Function of the Left Side of the Heart

Heart Failure
Boehringer Ingelheim4,200 enrolled638 locationsNCT06935370
Recruiting
Phase 3

Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity

ObesityOverweightAtherosclerotic Cardiovascular Disease
Amgen12,800 enrolled759 locationsNCT07037433
Recruiting
Phase 3

A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight and Type 2 Diabetes

Obesity or OverweightType 2 Diabetes Mellitus
Hoffmann-La Roche1,600 enrolled36 locationsNCT07351058
Recruiting
Phase 2

Efficacy and Safety of KAI-9531 Administered Once Weekly in Participants Living With Obesity Who Do Not Have Diabetes

Obesity
Kailera250 enrolled33 locationsNCT07458269
Recruiting
Phase 3

A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)

Metabolic Dysfunction-Associated Steatotic Liver Disease
Eli Lilly and Company4,500 enrolled561 locationsNCT07165028
Recruiting
Phase 3

A Phase III Study of AZD0780 on Major Adverse CV Events in Patients With a History of ASCVD Events or at High Risk for a First Event

Cardiovascular Disease
AstraZeneca15,100 enrolled1264 locationsNCT07000357
Recruiting
Phase 1

A Phase 1, Randomized, Double-blind, Placebo-controlled Study Evaluating AMG 691 in Healthy Participants and Participants With Mild-to-Moderate Asthma

Asthma
Amgen124 enrolled21 locationsNCT06637371
Recruiting
Phase 1

A Study to Evaluate the Effect of Moderate or Severe Hepatic Impairment on the Pharmacokinetics (PK) of Inavolisib

Hepatic Impairment
Genentech, Inc.32 enrolled4 locationsNCT07144111
Recruiting
Phase 1

A Study to Assess the Safety, Tolerability, and Pharmacokinetics of GIGA-2339 in Participants With Chronic Hepatitis B Virus Infection

Hepatitis B Virus Infection
GigaGen, Inc.48 enrolled16 locationsNCT07024641
Recruiting
Phase 1

A Study to Learn How the Body Processes the Study Medicine PF-07328948 in People With and Without Reduced Liver Function

HealthyHepatic Impairment
Pfizer26 enrolled3 locationsNCT07269301
Recruiting
Phase 1

A Study to Learn How the Body Processes the Study Medicine PF-07328948 in People With Reduced Kidney Function

HealthyRenal Impairment
Pfizer28 enrolled4 locationsNCT07315360
Recruiting
Phase 2

A Study to Compare Different Doses of RO7795081 With a Placebo or Semaglutide in People With Type 2 Diabetes

Type 2 Diabetes Mellitus
Hoffmann-La Roche240 enrolled51 locationsNCT07112872
Recruiting
Phase 3

VK2735 for Weight Management Type 2 Diabetes Phase 3 (VANQUISH 2)

Weight Loss
Viking Therapeutics, Inc.1,100 enrolled134 locationsNCT07104383
Recruiting
Phase 1

Single and Multiple Ascending Dose Study of AMG 513 in Participants With Obesity

Cardiometabolic disease
Amgen80 enrolled5 locationsNCT06585462
Recruiting
Phase 2

Aleniglipron Phase 2 in Type 2 Diabetes Mellitus

ObesityWeight LossObese+1 more
Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics50 enrolled17 locationsNCT07400588
Recruiting
Not Applicable

Gen 2 Battrode Wear Study

Adhesive Wear Time
Baxter Healthcare Corporation30 enrolled1 locationNCT07256951
Recruiting
Phase 2

To Evaluate the Safety and Efficacy of MANP in Subjects With Difficult to Control/ Resistant Hypertension

Difficult to Control Hypertension
E-Star BioTech, LLC120 enrolled29 locationsNCT06343298